Blood Flow Restriction Walking for stroke-related sarcopenia
Official title: Effects of Blood Flow Restriction Training on Physical Performance in Individuals With Stroke-Related Sarcopenia: A Randomized Controlled Trial
Run by The Hong Kong Polytechnic University · NCT06974461 · Data updated 2026-11-12
This study tests whether walking with blood flow restriction helps improve muscle strength and physical function in people who had a chronic stroke and have sarcopenia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | The Hong Kong Polytechnic University Academic / other |
| Locations | 2 sites (Hung Hom, Kowloon and 1 other locations) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | December 28, 2027 |
| Study ends | December 28, 2027 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT06974461 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with chronic stroke (≥6 months) who meet AWGS 2025 criteria for sarcopenia.
✕Probably not a fit
Patients without sarcopenia or those unable to tolerate BFR may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this randomized, sham-controlled trial, chronic stroke patients with sarcopenia will perform walking with blood flow restriction or a sham version to see if the intervention improves muscle strength and physical performance. Secondary outcomes will explore possible changes in muscle mass, vascular function, and quality of life. Eligibility requires chronic stroke status and sarcopenia defined by AWGS 2025 criteria. The Hong Kong Polytechnic University leads the trial in Hong Kong.
Why it matters
Potential benefit: If successful, patients may experience greater gains in strength and function from a low‑impact walking approach.
How similar studies have gone: Previous studies in related populations have shown signal of benefit with BFR approaches, but this exact protocol in chronic stroke with sarcopenia is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with chronic stroke (≥6 months post-stroke) * Sarcopenia will be diagnosed using the Asian Working Group for Sarcopenia (AWGS) 2025 criteria, defined as the concurrent presence of low muscle strength and low appendicular skeletal muscle mass. Muscle strength will be assessed using handgrip strength measured on the non-paretic side. Low muscle strength will be defined as handgrip strength \<28 kg for men and \<18 kg for women aged ≥65 years, and \<34 kg for men and \<20 kg for women aged 50-64 years. Appendicular skeletal muscle mass will be measured using bioelectrical impedance analysis, and the appendicular skeletal muscle mass index will be calculated as appendicular skeletal muscle mass divided by height squared. Low muscle mass will be defined as an appendicular skeletal muscle mass index \<7.0 kg/m² for men and \<5.7 kg/m² for women aged ≥65 years, and \<7.6 kg/m² for men and \<5.7 kg/m² for women aged 50-64 years. Exclusion Criteria: * Stroke occurred within the past 6 months * Resting systolic blood pressure \> 200 mmHg * Resting diastolic blood pressure \> 100 mmHg * Presence of implanted electronic or metallic devices that interfere with blood flow restriction cuffs * Contraindication to bioelectrical impedance analysis (e.g., pacemaker, ICD)
Where it's running
-
Hong Kong Polytechnic University
Hung Hom, Kowloon, Hong Kong Recruiting -
Hong Kong Polytechnic University
Hung Hom, Kowloon, Hong Kong Not yet recruiting
Study contacts
- Study coordinator: Yingxiu Diao, Master
- Email: 24039355r@connect.polyu.hk
- Phone: +8614796733917
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sarcopenia in Patients After Cardiac Surgery
This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.
-
Bone marrow mesenchymal stem cell injection for sarcopenia
This study tests whether CG-BM1, a stem cell injection, can be safely given to adults with sarcopenia to see if it helps improve muscle health.
-
GLP-1 receptor agonist use and muscle health in adults with obesity without diabetes
This study tests whether GLP-1 receptor agonists affect muscle mass and strength in adults with obesity who don’t have diabetes.
-
Sarcopenia and Epidural Steroid Injections in Lumbar Spinal Stenosis
We’re testing how sarcopenia relates to pain, function, and quality of life after a routine interlaminar epidural steroid injection in people with lumbar spinal stenosis.
-
Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients
This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.
-
Lower-limb rehabilitation robot training with nutrition education for sarcopenia
In adults aged 60 and older with sarcopenia, this study tests whether adding robot-assisted leg training to nutrition education can improve muscle mass and walking ability compared with usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.